The phrase "a lower tolerability" is correct and usable in written English.
It can be used when discussing the acceptability or endurance of something, often in a comparative context.
Example: "The new medication has a lower tolerability compared to the previous one, leading to more side effects for patients."
Alternatives: "reduced tolerability" or "diminished tolerability".
Patients treated with enalapril had a shorter treatment period, indicating a lower tolerability for enalapril compared with candesartan.
Nevertheless, the type and frequency of adverse events reported is consistent in both age groups and indicate a lower tolerability of MAS3 as compared to DHA-PPQ.
We hypothesized that the differences in mean average DDD between those using metformin (0.7) and those using sulfonylurea derivatives (1.5) could be partly explained by a lower tolerability of participants to metformin compared with sulfonylurea derivatives.
As regards harms, the findings were similar to those on H5N1 vaccination: both meta-analyses found a higher (and high) frequency of mild or moderate adverse events by oil-in-water adjuvants, although they concluded that such a lower tolerability could be acceptable in a pandemic, and a low rate of serious adverse events (three, all solved in 10 d, out of 22,826 vaccinated subjects).
We expected that the vasodilatory effects of carvedilol might lead to lower tolerability as a result of hypotension.
The major explanation for this finding may be that older patients tend to have poorer physical condition, other associated comorbidities and lower tolerability for systemic treatment.
However, the widespread use of platinum-based treatments has been undermined by the alleged lower tolerability of these regimens and the requirement for prolonged infusion protocols.
As older patients may tend to have lower tolerability for treatment combinations, the association between age and cumulatively delivered 5-FU dose (<80 vs ⩾80% of planned dose) was investigated in a cross-table.
In general, erlotinib is associated with higher toxicity and lower tolerability than gefitinib because the dose of erlotinib used is nearly equal to the maximum tolerated dose, whereas the dose of gefitinib used is close to the minimum active dose [ 11, 12].
All randomized, controlled clinical trials of aliskiren (evidence level 2) were included for analysis of efficacy with the selected outcomes of blood pressure lowering, tolerability, and adherence; all other publications were excluded.
OXC has a comparable efficacy to that of CBZ but a greater tolerability and a lower potential for drug interaction [23 25].
